المؤلفون: E. Kovalenko I., E. Artamonova V., L. Bolotina V., L. Zhiliaeva A., D. Ponomarenko M., E. Karabina V., G. Mukhametshina Z., A. Khasanova I., E. Ratner Yu., A. Safarova R., A. Manikhas G., N. Popova O., I. Evstigneeva V., L. Vladimirova Yu., L. Kramskaya V., T. Karandeeva V., I. Suslova R., O. Romanchuk V., V. Shikina E., A. Povyshev Yu., M. Osipov A., E. Cherniakova M., A. Dergunov S., M. Volkonskiy V., I. Chernov S., I. Shumskaya E., M. Fael M., V. Garifullina I., I. Gudkova E., Е. Коваленко И., Е. Артамонова В., Л. Болотина В., Л. Жиляева А., Д. Пономаренко М., Е. Карабина В., Г. Мухаметшина З., А. Хасанова И., Е. Ратнер Ю., А. Сафарова Р., А. Манихас Г., Н. Попова О., И. Евстигнеева В., Л. Владимирова Ю., Л. Крамская В., Т. Карандеева В., И. Суслова Р., О. Романчук В., В. Шикина Е., А. Повышев Ю., М. Осипов А., Е. Чернякова М., А. Дергунов С., М. Волконский В., И. Чернов С., И. Шумская Э., М. Фаель М., В. Гарифуллина И., И. Гудкова Е.

المساهمون: Данная публикация подготовлена при финансовой поддержке компании «Эйсай».

المصدر: Meditsinskiy sovet = Medical Council; № 20 (2021); 36-46 ; Медицинский Совет; № 20 (2021); 36-46 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: breast cancer, eribulin, trastuzumab, efficacy, tolerance, рак молочной железы, эрибулин, трастузумаб, эффективность, переносимость

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6578/5961; Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182. https://doi.org/10.1126/science.3798106.; Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792. https://doi.org/10.1056/NEJM200103153441101.; Seidman A., Hudis C., Pierri M.K., Shak S., Paton V., Ashby M. et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–1221. https://doi.org/10.1200/JCO.2002.20.5.1215.; Cortazar P., Justice R., Johnson J., Sridhara R., Keegan P., Pazdur R. US Food and Drug Administration approval overview in metastatic breast cancer. J Clin Oncol. 2012;30(14):1705–1711. https://doi.org/10.1200/JCO.2011.39.2613.; Infante J.R., Yardley D.A., Burris H.A. 3rd, Greco F.A., Farley C.P., Webb C. et al. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer. Clin Breast Cancer. 2009;9(1):23–28. https://doi.org/10.3816/CBC.2009.n.004.; Livingston R.B., Barlow W.E., Kash J.J., Albain K.S., Gralow J.R., Lew D.L. et al. SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. Breast Cancer Res Treat. 2011;130(1):123–131. https://doi.org/10.1007/s10549-011-1698-5.; Swain S.M., Baselga J., Kim S.B., Ro J., Semiglazov V., Campone M. et al. CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2- positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–734. https://doi.org/10.1056/NEJMoa1413513.; Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–2743. https://doi.org/10.1056/NEJMoa064320.; Lewis Phillips G.D., Li G., Dugger D.L., Crocker L.M., Parsons K.L., Mai E. et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280–9290. https://doi.org/10.1158/0008-5472.CAN-08-1776.; Barok M., Tanner M., Köninki K., Isola J. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res. 2011;13(2):R46. https://doi.org/10.1186/bcr2868.; Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J. et al.; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791. https://doi.org/10.1056/NEJMoa1209124.; Krop I.E., Kim S.B., Martin A.G., LoRusso P.M., Ferrero J.M., BadovinacCrnjevic T. et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18(6):743–754. https://doi.org/10.1016/S1470-2045(17)30313-3.; Modi S., Saura C., Yamshita T., Park Y.H., Kim S., Tamura K. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020;382:610–621. https://doi.org/10.1056/NEJMoa1914510.; Murthy R.K., Loi S., Okines A., Paplomata E., Hamilton E., Hurvitz S.A. et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020;382:597–609. https://doi.org/10.1056/NEJMoa1914609.; Giordano S.H., Temin S., Chandarlapaty S., Crews J.R., Esteva F.J., Kirshner J.J. et al. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36(26):2736–2740. https://doi.org/10.1200/JCO.2018.79.2697.; Kaufman P.A., Awada A., Twelves C., Yelle L., Perez E.A., Velikova G. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594–601. https://doi.org/10.1200/JCO.2013.52.4892.; Twelves C., Cortes J., Vahdat L., Olivo M., He Y., Kaufman P.A., Awada A. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat. 2014;148(3):553–561. https://doi.org/10.1007/s10549-014-3144-y.; Pivot X., Marmé F., Koenigsberg R., Guo M., Berrak E., Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol. 2016;27(8):1525–1531. https://doi.org/10.1093/annonc/mdw203.; Wilks S., Puhalla S., O’Shaughnessy J., Schwartzberg L., Berrak E., Song J. et al. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2- positive breast cancer. Clin Breast Cancer. 2014;14(6):405–412. https://doi.org/10.1016/j.clbc.2014.04.004.; Inoue K., Ninomiya J., Saito T., Okubo K., Nakakuma T., Yamada H. et al.; SBCCSG-36 investigators. Eribulin, trastuzumab, and pertuzumab as firstline therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial. Invest New Drugs. 2019;37(3):538–547. https://doi.org/10.1007/s10637-019-00755-x.; Yamashita T., Masuda N., Saji S., Araki K., Ito Y., Takano T. et al. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). Trials. 2020;21(1):391. https://doi.org/10.1186/s13063-020-04341-y.; Lutrino E.S., Orlando L., Febbraro A., Giampaglia M., Zamagni C., Schiavone P. et al. Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience. Tumori. 2020;106(4):301–305. https://doi.org/10.1177/0300891619887225.; Коваленко Е.И., Артамонова Е.В., Карабина Е.В., Андреяшкина И.И., Прокофьева Е.А., Попова Н.О. и др. Эффективность комбинации эрибулина и трастузумаба при HER2-положительном диссеминированном раке молочной железы: результаты российского наблюдательного исследования. Современная онкология. 2020;22(1):29–35. https://doi.org/10.26442/18151434.2020.1.200058.; Krop I.E., Kim S.B., González-Martín A., LoRusso P.M., Ferrero J.M., Smitt M. et al.; TH3RESA study collaborators. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(7):689–699. https://doi.org/10.1016/S1470-2045(14)70178-0.; Mougalian S.S., Copher R., McAllister L., Radtchenko J., Wang E.C., Broscious M. et al. Outcomes of real-world use of eribulin plus trastuzumab for HER2-positive metastatic breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4–8; San Antonio, TX. Philadelphia (PA)AACR. Cancer Res. 2019;79(4 Suppl.):17–28. https://doi.org/10.1158/1538-7445.SABCS18-P6-17-28.; https://www.med-sovet.pro/jour/article/view/6578

الاتاحة: https://www.med-sovet.pro/jour/article/view/6578
https://doi.org/10.21518/2079-701X-2021-20-36-46

المؤلفون: L. Manzyuk V., E. Kovalenko I., V. Gorbunova A., L. Bolotina V., T. Semiglazova Y., L. Zhilyaeva A., Y. Mishina A., D. Ponomarenko M., V. Goldberg E., N. Popova O., E. Karabina V., G. Mukhametshina Z., A. Khasanova I., S. Safina Z., M. Shaidorov V., L. Vladimirova Y., I. Mitashok S., E. Prokofieva P., I. Evstigneeva V., I. Andreyashkina I., N. Abramova A., I. Popova L., A. Teterich A., E Gaisina A., V. Chubenko A., S. Limareva V., N. Tikhanovskaya M., A. Storozhakova E., N. Samaneva Y., Y. Svetitskaya V., T. Snezhko A., E. Kalabanova A., A. Povyshev Y., I. Yudina V., L. Vorotilina V., T. Andreeva V., G. Tumanyan C., A. Kozyakov E., L. Gilmutdinova A., Л. Манзюк В., Е. Коваленко И., В. Горбунова А., Л. Болотина В., Т. Семиглазова Ю., Л. Жиляева А., Ю. Мишина А., Д. Пономаренко М., В. Гольдберг Е., Н. Попова О., Е. Карабина В., Г. Мухаметшина З., А. Хасанова И., С. Сафина З., М. Шайдоров В., Л. Владимирова Ю., И. Миташок С., Е. Прокофьева П., И. Евстигнеева В., И. Андреяшкина И., Н. Абрамова А., И. Попова Л., А. Тетерич А., Е. Гайсина А., В. Чубенко А., С. Лимарева В., Н. Тихановская М., А. Сторожакова Э., Н. Саманева Ю., Я. Светицкая В., Т. Снежко А., Е. Калабанова А., А. Повышев Ю., И. Юдина В., Л. Воротилина В., Т. Андреева В., Г. Туманян С., А. Козяков Е., Л. Гильмутдинова А.

المصدر: Malignant tumours; № 3 (2017); 46-56 ; Злокачественные опухоли; № 3 (2017); 46-56 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: metastatic breast cancer, chemotherapy, eribulin, метастатический рак молочной железы, химиотерапия, эрибулин

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/391/337; Cardoso F., Harbeck N., Fallowfield L., Kyriakides S., Senkus E. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 2012, Vol. 23, pp. vii11–vii19.; Cortes J., O’Shaughnessy J., Loesch D. et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study, Lancet, 2011, Vol. 377, pp. 914–923.; Kaufman P. A., Awada A., Twelves C. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane, J. Clin. Oncol., 2015, Vol. 33, pp. 594–601.; Twelves C., Awada A., Cortes J., Yelle I., Velikova G., Olivo M., Song J., Dutcus C., Kaufman P. Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer, Breast Cancer: Basic and Clinical Research, 2016, Vol. 10, pp 77–84.; Twelves C., Cortes J., Vandat L. et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res. Treat., 2014, Vol. 148, pp. 553–561.; Pivot X., Marm F., Koenigsberg R., Guo M., Berrak E., Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy, Annals of Oncology, 2016, Vol. 27, pp. 1525–1531.; Wilks Sh., Puhalla Sh., O’Shaughnessy J. et al. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer, Clin. Breast Cancer, 2014, Vol. 14, No. 6, pp. 405–412.; Инструкция по медицинскому применению препарата Халавен® (РУ ЛП-001782 от 28.07.2012, с изменениями от 08.02.2017). [Instructions for the medical use of the drug Halaven® (RU LP-001782 dated 28.07.2012, as amended on 08.02.2017) (In Russ.)]; Blum J. L., Twelves C. J., Dutcus C. et al. Impact of the number of prior chemotherapy regimens on overall survival (OS) among subjects with locally recurrent or MBC treated with eribulin mesylate: results from the Phase III EMBRACE study. Presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), December 8–12, 2010, San Antonio, TX, USA, P6-13–01.; Towle M. J., Salvato K. A., Wels B. F. et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions, Cancer Res., 2011, Vol. 71. No. 2. pp. 496–505.; Funahashi Y., Okamoto K., Adachi Y. et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models, Cancer Sci., 2014, Vol. 105. No. 10. pp. 1334–1342.; Ueda S., Saeki T., Takeuchi H. et al. In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients a comparison to bevacizumab, Br. J. Cancer, 2016, Vol. 114, pp. 1212–1218.; Yoshida T., Ozawa Y., Kimura T. et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial – mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states, Br. J. Cancer, 2014, Vol. 110, pp. 1497–505.; https://www.malignanttumors.org/jour/article/view/391

الاتاحة: https://www.malignanttumors.org/jour/article/view/391
https://doi.org/10.18027/2224-5057-2017-3-46-56